Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript
11:21pm, Monday, 10'th Nov 2025
Capricor Therapeutics, Inc. ( CAPR ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marbán - Co-Founder, President, CEO &
Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm
10:16am, Monday, 10'th Nov 2025
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) br
Caprock Announces Option and RSU Grant
07:56am, Wednesday, 05'th Nov 2025
Toronto, Ontario--(Newsfile Corp. - November 5, 2025) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") announces that its
–Publication highlights Deramiocel's anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development–
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
09:15am, Friday, 31'st Oct 2025
Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET
Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last?
10:26am, Thursday, 30'th Oct 2025
Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm
02:20pm, Tuesday, 28'th Oct 2025
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) bre
KLP Kapitalforvaltning AS Boosts Stock Position in Capricor Therapeutics, Inc. $CAPR
03:02am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS lifted its position in Capricor Therapeutics, Inc. (NASDAQ: CAPR) by 65.2% in the second quarter, according to its most recent filing with the Securities and Exchange Commiss
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of “Moderate Buy” from Brokerages
01:32am, Wednesday, 22'nd Oct 2025
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are currently covering the company, MarketBe
Capricor allegedly misled investors about its DMD therapy's FDA approval prospects; an FDA rejection letter citing lack of efficacy data sent shares down.
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) shareholders, concerning alleged misco
Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026
03:51pm, Monday, 29'th Sep 2025
Capricor Therapeutics is advancing deramiocel (CAP-1002) for DMD cardiomyopathy, with a BLA resubmission and HOPE-3 topline data expected by 2026. CAPR's therapy addresses a critical unmet need in non
Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway
09:08am, Monday, 29'th Sep 2025
Based on prior, preclinical and clinical data, including 2 small randomized trials, I believe there is a high probability that Capricor Therapeutics' phase 3 trial will be positive. Topline results ar
Capricor (CAPR) Surges 5.3%: Is This an Indication of Further Gains?
07:46am, Friday, 26'th Sep 2025
Capricor (CAPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Capricor Therapeutics, Inc. - Special Call
11:07am, Thursday, 25'th Sep 2025
Capricor Therapeutics, Inc. - Special Call Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marbán - Co-Founder, President, CEO & Director Conference Call Participants Joseph P
